An early-stage biotech venture firm, navigating a challenging capital environment, sought to enhance its data strategy to support ongoing investments and future fundraising.
With a broadened investment scope—from pre-IND startups to later-stage private and public opportunities—the firm required more robust tools for screening, diligence, and competitive intelligence.
Read on to see how a strategic shift empowered the firm to make sharper, data-driven investment decisions across a wider range of biotech opportunities.
